RVTY vs. AVTR, BIO.B, BIO, WAT, ILMN, TXG, FMS, SWAV, SRPT, and MEDP
Should you be buying Revvity stock or one of its competitors? The main competitors of Revvity include Avantor (AVTR), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Waters (WAT), Illumina (ILMN), 10x Genomics (TXG), Fresenius Medical Care (FMS), Shockwave Medical (SWAV), Sarepta Therapeutics (SRPT), and Medpace (MEDP). These companies are all part of the "medical" sector.
Avantor (NYSE:AVTR) and Revvity (NYSE:RVTY) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.
In the previous week, Avantor and Avantor both had 6 articles in the media. Avantor's average media sentiment score of 1.23 beat Revvity's score of 1.04 indicating that Revvity is being referred to more favorably in the news media.
95.1% of Avantor shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 1.5% of Avantor shares are held by insiders. Comparatively, 0.6% of Revvity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Revvity has lower revenue, but higher earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.
Avantor has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Revvity has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.
Avantor received 156 more outperform votes than Revvity when rated by MarketBeat users. Likewise, 63.64% of users gave Avantor an outperform vote while only 54.55% of users gave Revvity an outperform vote.
Avantor currently has a consensus target price of $26.71, indicating a potential upside of 8.59%. Revvity has a consensus target price of $118.17, indicating a potential upside of 13.63%. Given Avantor's higher possible upside, analysts plainly believe Revvity is more favorable than Avantor.
Revvity has a net margin of 5.49% compared to Revvity's net margin of 3.79%. Revvity's return on equity of 13.01% beat Avantor's return on equity.
Summary
Avantor beats Revvity on 10 of the 17 factors compared between the two stocks.
Get Revvity News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVTY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVTY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
